संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

contract pharmacy services-pa - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine hydrochloride 150 mg - ranitidine tablets are indicated in: 1. short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of rantidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acuter ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). 4. short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

apotex nz ltd - oxybutynin hydrochloride 1 mg/ml;   - syrup - 1 mg/ml - active: oxybutynin hydrochloride 1 mg/ml   excipient: berry flavour (mix) 538632 citric acid monohydrate fast green fcf glycerol methyl hydroxybenzoate purified water sodium citrate dihydrate sorbitol as 70% solution, 366 mg/ml sucrose - oxybutynin chloride is indicated in adults and children over 5 years of age for the management of urgency and incontinence that characterise neurogenic bladder disorders and idiopathic destrusor instability.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

clinect nz pty limited - oxybutynin hydrochloride 5mg (plus 2% overage to allow for water content) - tablet - 5 mg - active: oxybutynin hydrochloride 5mg (plus 2% overage to allow for water content) excipient: brilliant blue fcf lactose monohydrate magnesium stearate microcrystalline cellulose - oxybutynin chloride is indicated in adults and children over 5 years of age for the management of urgency and incontinence that characterise neurogenic bladder disorders and idiopathic destrusor instability.

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - ranitidine hydrochloride - solution for injection - 25mg/1ml

कनाडा - अंग्रेज़ी - Health Canada

boumatic llc - lactic acid; sodium chlorite - solution - 2.64%; 0.64% - lactic acid 2.64%; sodium chlorite 0.64% - cattle

कनाडा - अंग्रेज़ी - Health Canada

pro doc limitee - ranitidine (ranitidine hydrochloride) - tablet - 150mg - ranitidine (ranitidine hydrochloride) 150mg - histamine h2-antagonists

कनाडा - अंग्रेज़ी - Health Canada

pro doc limitee - ranitidine (ranitidine hydrochloride) - tablet - 300mg - ranitidine (ranitidine hydrochloride) 300mg - histamine h2-antagonists

कनाडा - अंग्रेज़ी - Health Canada

teva canada limited - ranitidine (ranitidine hydrochloride) - tablet - 150mg - ranitidine (ranitidine hydrochloride) 150mg - histamine h2-antagonists

कनाडा - अंग्रेज़ी - Health Canada

teva canada limited - ranitidine (ranitidine hydrochloride) - tablet - 300mg - ranitidine (ranitidine hydrochloride) 300mg - histamine h2-antagonists

कनाडा - अंग्रेज़ी - Health Canada

cobalt pharmaceuticals company - ranitidine (ranitidine hydrochloride) - tablet - 150mg - ranitidine (ranitidine hydrochloride) 150mg - histamine h2-antagonists